Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 10/20 | 0.52 |
| ▸ | F2 | P00734 | 7/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.52 |
| ▸ | PLG | P00747 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851954 | 0.95 | ST14 (0.48) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL850947 | 0.95 | ST14 (0.55) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851366 | 0.95 | ST14 (0.50) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851641 | 0.95 | ST14 (0.47) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851737 | 0.94 | ST14 (0.57) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851275 | 0.94 | ST14 (0.49) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851754 | 0.93 | ST14 (0.46) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851621 | 0.92 | ST14 (0.50) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851346 | 0.92 | ST14 (0.48) | ST14F2PRSS1PRSS2PRSS3 | |
| SCHEMBL851365 | 0.92 | ST14 (0.50) | ST14F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | ST14 216/4885F2 112/4885PRSS1 3/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | ST14 216/4885F2 112/4885PRSS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.